Market Analysis: Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
Market Definition: Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
Chronic inflammatory demyelinating polyneuropathy is a neurological disorder in which the body immune system attacks myelin which is an important part of the nervous system. It happens when the body immune system cannot differentiate between the body’s own cell and foreign cell and instead start destroying the healthy cells of the body. This can cause pain, impaired ability, loss of sensation, chronic fatigue and other problems, Different treatments can be used to treat this disease such as intravenous immunoglobulin, plasmapheresis, physiotherapy and others.
Get More Insights About Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Request Sample @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
Increasing cases of autoimmune diseases will drive the growth of this marker
Rising awareness among population about CIPD will also accelerate the market growth
Increasing R&D associated with the plasma-derived medicines is also enhancing the market growth
Growing government support via awareness programs and drug approvals will also propel the market growth
Side effect related to the Intravenous Immunoglobulin (IVIG) treatment will hinder the growth of this market
High cost of the treatment of CIPD will also restrain the market growth
Availability of limited treatment options will also hinder the growth of this market
Segmentation: Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
Spinal Fluid Analysis
By Route of Administration
By End- User
Specialty Neurological Clinics
Research & Academic Laboratories
Rest of Europe
Rest of Asia-Pacific
Rest of South America
Middle East and Africa
Rest of Middle East and Africa
Key Developments in the Market:
In March 2018, CSL Behring announced that they have received approval from the Food and Drug Administration Hizentra which is a treatment specially designed for the chronic inflammatory demyelinating polyneuropathy. This is very beneficial for the patients for the CIPD as it eliminates the need of traveling to the infusion center or hospital as they can slef- administers their treatment
In August 2015, Pfizer announced that they have received orphan drug designation from the US Food and Drug Administration (FDA) for the autoimmune candidate GL-2045. This GL- 2045 which is specially designed to treat chronic inflammatory demyelinating polyneuropathy (CIDP). This orphan drug designation was essential because it offers countless incentives to develop GL-2045 to tackle an unmet need in CIDP
Key Market Competitors:
Few of the major competitors currently working in the global chronic inflammatory demyelinating polyneuropathy (CIDP) market are Grifols, S.A., Pfizer Inc., CSL, GeNeuro SA, Momenta Pharmaceuticals, Teijin Pharma Limited., ImmuPharma PLC, UCB S.A., Protagen, AstraZeneca, F. Hoffmann-La Roche Ltd, Biogen International, Gliknik Inc., Creative Diagnostics, Novartis AG, Kedrion S.p.A., Octapharma, argenx among others.
Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.
Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.
Browse Trending Related Reports @
About Data Bridge Market Research: